Cutler Group LP Affimed N.V. Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$1.96 - $3.32 $2,352 - $3,984	-1,200 Reduced 10.78%	9,936 $20,000
Q2 2022 Aug 04, 2022	BUY	$2.27 - $4.86 $15,290 - $32,736	6,736 Added 153.09%	11,136 $30,000
Q2 2021 Jul 19, 2021	BUY	$7.78 - $11.4 $34,232 - $50,160	4,400 New	4,400 $37,000
Q1 2019 May 10, 2019	SELL	$3.05 - $4.34 $915 - $1,302	-300 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$2.82 - $4.67 $846 - $1,401	300 New	300 $0

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.